8-K: Windtree Therapeutics Secures High-Interest Convertible Debt Amidst CFO Resignation and $3 Million Property Dispute

Windtree Therapeutics, Inc. has entered into a high-interest convertible note and warrant financing agreement for $150,000, while simultaneously announcing the resignation of its CFO and a dispute over a $3 million earnest money payment related to a terminated real estate deal.

Summary

• Windtree Therapeutics, Inc. (the 'Company') secured $150,000 in gross proceeds through the issuance of two Senior Unsecured Convertible Promissory Notes and associated Warrants on June 24, 2025.
• The Convertible Promissory Notes have a total principal amount of $174,419, accrue interest at 14% per annum (compounding quarterly), and mature in 12 months; the interest rate increases to 24% upon an Event of Default.
• The notes are convertible into Common Stock at a price of $0.587 per share.
• Warrants were issued entitling holders to purchase Common Stock valued at 75% of the purchase price paid for the notes (totaling $112,500 worth of shares), with an exercise price of $0.587 per share.
• The $150,000 in proceeds will be used to fund the Company's operational expenses.
• Payments on these new notes are subordinated to the repayment of all outstanding obligations under a convertible promissory note with DFU, LLC dated June 6, 2025.
• The Company is currently disputing a $3 million earnest money demand from TBB Crescent Park Drive LLC following the termination of a real estate purchase agreement for a property in Houston, Texas.
• Jamie McAndrew resigned from her position as Senior Vice President, Chief Financial Officer, and Corporate Secretary, effective June 25, 2025, with Jed Latkin (President and CEO) assuming interim principal financial officer responsibilities.

Sentiment

Score: 3

Explanation: While the Company secured immediate funding, the terms of the financing are highly unfavorable (high interest rate, significant dilution), indicating financial distress. This, coupled with a material legal dispute and a CFO resignation, points to significant operational and financial challenges, outweighing the positive of securing capital.

Positives

• The Company successfully secured $150,000 in gross proceeds, providing immediate liquidity for operational expenses.
• The financing structure includes conversion rights for the holders, offering a potential path for the debt to convert into equity.

Negatives

• The 14% annual interest rate on the convertible notes, escalating to 24% upon default, indicates a high cost of capital and significant perceived risk by the investors.
• The issuance of warrants for 75% of the purchase price represents substantial equity dilution for existing shareholders.
• The Company is engaged in a dispute over a $3 million earnest money payment, which could result in a material financial loss.
• The resignation of the Chief Financial Officer and the interim assumption of her duties by the CEO may signal instability in the Company's financial leadership and operations.
• The new notes are explicitly junior to a prior convertible promissory note with DFU, LLC, meaning the Company must repay that obligation first before any payments on the new debt.

Risks

• **Default Risk**: The notes carry a high interest rate (14%, escalating to 24% upon default) and numerous 'Events of Default' clauses, including failure to pay, failure to issue shares upon conversion, breach of covenants/representations, judgments over $50,000, bankruptcy, delisting from NASDAQ, failure to comply with Exchange Act reporting, loss of DTC eligibility, cessation of operations, failure to maintain material intellectual property/assets, financial statement restatement, transfer agent issues, cessation of trading, cross-default with other agreements, disclosure of material non-public information, and reverse stock splits.
• **Dilution Risk**: Significant potential for future dilution of existing shareholders due to the conversion of the notes and the exercise of the warrants, especially given anti-dilution provisions for future equity sales below the conversion/exercise price.
• **Liquidity Risk**: The proceeds are designated for 'operational expenses,' suggesting an ongoing need for funding, and the subordination to a prior note indicates existing debt obligations that must be satisfied first.
• **Legal and Financial Dispute Risk**: The ongoing dispute over a $3 million earnest money payment could result in a substantial financial liability for the Company.
• **Operational and Management Risk**: The resignation of the CFO and the interim appointment of the CEO to financial duties could strain management resources and potentially impact the quality and timeliness of financial reporting.
• **Market and Listing Risk**: Explicit risks include trading market limitations on share issuance (Maximum Share Amount) and the potential for delisting from NASDAQ if compliance is not maintained.

Future Outlook

The Company intends to use the $150,000 in proceeds to fund operational expenses, indicating a focus on maintaining current business activities. The Company has committed to filing a registration statement for the resale of the Conversion Shares and Warrant Shares, maintaining its NASDAQ listing, and complying with Exchange Act reporting requirements, suggesting an intent to remain a publicly traded entity and facilitate liquidity for investors. The ongoing dispute over the $3 million earnest money introduces financial uncertainty.

Management Comments

• Jed Latkin, President and Chief Executive Officer, will assume the responsibilities of principal financial officer on an interim basis following the CFO's resignation.
• The Company affirms all its obligations to the Holder under all Transaction Documents and states that no default or Event of Default has occurred as of the Issue Date.

Industry Context

This financing event is characteristic of a small-cap biotechnology or pharmaceutical company, such as Windtree Therapeutics, which often relies on dilutive debt and equity instruments to fund ongoing research, development, and operational expenses, especially when pre-revenue or with limited commercial products. The high interest rate and significant warrant coverage reflect the inherent high-risk profile associated with early-stage or financially challenged companies in the life sciences sector, where capital access can be constrained and terms are often less favorable than for established, profitable entities. The CFO transition and legal dispute add layers of complexity not uncommon in companies facing financial pressures.

Comparison to Industry Standards

• The 14% annual interest rate, escalating to 24% upon default, is substantially higher than typical corporate debt rates for financially stable companies, indicating a high-risk lending scenario. For comparison, investment-grade corporate bonds might yield 3-6%, while even high-yield (junk) bonds typically range from 7-12%.
• The issuance of warrants equal to 75% of the purchase price is a very aggressive equity sweetener, far exceeding standard warrant coverage (which might be 10-30%) in more conventional financings, highlighting the Company's urgent need for capital and willingness to offer significant upside to attract investors.
• The conversion price of $0.587 per share, which is likely at or near the current market price, combined with the warrant exercise price, suggests a 'death spiral' or highly dilutive financing structure, common for companies with limited alternatives, unlike more favorable financings seen in robust biotech companies with strong pipelines or commercial products.
• The subordination of this new debt to a prior convertible note (DFU, LLC) indicates a complex and potentially strained capital structure, which is less common for companies with strong balance sheets and more straightforward debt arrangements.
• The CFO resignation and interim appointment of the CEO to financial duties is a red flag for corporate governance and operational stability, contrasting with well-managed companies that ensure seamless transitions in key leadership roles.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is disputing a demand from TBB Crescent Park Drive LLC for $3 million in earnest money related to the termination of a real estate Purchase and Sale Agreement dated June 28, 2024.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of notes and exercise of warrants, which could negatively impact share price. The high cost of capital and the legal dispute also pose risks to shareholder value.
• **New Note Holders**: Benefit from a high interest rate (14-24%) and substantial equity upside through conversion rights and warrants, but their payments are subordinated to a prior note.
• **DFU, LLC (Prior Note Holder)**: Their existing convertible promissory note must be repaid in full before any payments are made on the newly issued notes, indicating a senior position in the Company's debt structure.
• **Employees**: The $150,000 in proceeds is allocated for operational expenses, which may help maintain short-term employment and business continuity. However, the CFO resignation could create uncertainty.
• **Creditors (TBB Crescent Park Drive LLC)**: Are in a dispute with the Company over a $3 million earnest money payment, which could result in litigation and impact the Company's financial standing.

Next Steps

• The Company will use the $150,000 in proceeds to fund operational expenses.
• The Company must repay all outstanding obligations under the convertible promissory note with DFU, LLC dated June 6, 2025, before any payments on the newly issued notes.
• The Company is required to file a registration statement (Form S-1 or S-3) within 20 Trading Days from June 24, 2025, to register the offering and resale of the Conversion Shares and Warrant Shares.
• The Company is obligated to maintain the listing of its Common Stock on the NASDAQ stock market.
• The Company must comply with the reporting requirements of the Exchange Act.
• The Company will maintain engagement with a PCAOB registered accounting firm.
• Jed Latkin will continue to serve as the interim principal financial officer.
• The Company will continue to dispute TBB Crescent Park Drive LLC's entitlement to the $3 million earnest money.

Key Dates

Recommendation

Keywords

Windtree Therapeutics, WINT, Convertible Promissory Note, Warrants, Capital Raise, Debt Financing, Equity Financing, SEC Filing, 8-K, CFO Resignation, Real Estate Dispute, Dilution, Corporate Governance, Financial Reporting